CN1386510A - Composition of suppressing infection, and veberage and food contg. same - Google Patents
Composition of suppressing infection, and veberage and food contg. same Download PDFInfo
- Publication number
- CN1386510A CN1386510A CN02121607A CN02121607A CN1386510A CN 1386510 A CN1386510 A CN 1386510A CN 02121607 A CN02121607 A CN 02121607A CN 02121607 A CN02121607 A CN 02121607A CN 1386510 A CN1386510 A CN 1386510A
- Authority
- CN
- China
- Prior art keywords
- isotoadstool
- heat treated
- extract
- sporophore
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract description 18
- 235000013305 food Nutrition 0.000 title abstract description 8
- 208000015181 infectious disease Diseases 0.000 title description 14
- 241000194032 Enterococcus faecalis Species 0.000 claims abstract description 25
- 241000186660 Lactobacillus Species 0.000 claims abstract description 25
- 229940032049 enterococcus faecalis Drugs 0.000 claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 25
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 36
- 230000005764 inhibitory process Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 26
- 229940039696 lactobacillus Drugs 0.000 claims description 22
- 230000037213 diet Effects 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 3
- 244000052769 pathogen Species 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 4
- 230000002924 anti-infective effect Effects 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 241000186779 Listeria monocytogenes Species 0.000 description 15
- 229940115931 listeria monocytogenes Drugs 0.000 description 15
- 238000002372 labelling Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000222501 Agaricaceae Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This invention provides an anti-infection composition which exhibits excellent property of anti-infection against pathogen bacteria, and food containing such composition, which can be taken orally. The composition contains the fruiting body and/or the extract of mycelium culture of Agaricus blazei Murill and a heat-treated cell mass of Lactobacilli as effective components. Among the said Lactobacilli, Enterococcus faecalis is preferable. Preferably, the content of the said fruiting body and/or mycelium culture extract is 0. 5 to 99.5 mass %, the heat treated cell mass of said Lactobacilli is 99.5 to 0.5 mass %.
Description
Technical field
The heat treated thalline that the present invention relates to isotoadstool (Agaricus blazei Murill) extract and lactobacillus is the inhibition infected group compound of effective ingredient and the diet product that contain said composition.
Background technology
As everyone knows, the isotoadstool (Agaricus blazei Murill) that belongs to Basidiomycetes Agaricaceae fungus is to have cancer, anaphylaxis, diabetes, the prevention of hypertension etc. and the composition of therapeutic effect, for example, as anti-tumor active ingredient, can isolate acidic polysaccharose body (open the clear 64-67194 of communique number of Japan Patent) from its sporophore respectively, neutral polysaccharide body (open the clear 64-67195 of communique number of Japan Patent) and proteoglycan body (open the flat 2-78630 of communique number of Japan Patent), from mycelium, isolate proteoglycan body (open the clear 61-47518 of communique number of Japan Patent), further from mycelial culturing filtrate, isolate proteoglycan body (open the clear 61-47519 of communique number of Japan Patent).
Isotoadstool is widely used as the health food raw material.For example, Japan Patent is open to have disclosed that the use solvent extracts gill fungi under pressurized conditions for communique 2001-103927 number, with 50% ethanol this extract is handled then, again gained gill fungi extractum is sneaked into food and the edible composition that makes.
Japan Patent has disclosed the healthy beverage food that contains gill fungi open communique 2001-17130 number, and the feature of this healthy beverage food is to have sneaked into vinegar and Mel in the decocting liquid of gill fungi.
Japan Patent has openly disclosed for the flat 11-32723 of communique number and has utilized the enzyme based on hemicellulase that mycelium, sporophore and their mixture of gill fungi or their cultivation residual liquid are carried out resolution process, obtaining beta glucan, is the health food of main constituent with the biological active substances that contains a large amount of this beta glucans.
In addition, lactobacillus is also extensively absorbed as health food, has balance, the generation that reduces the enteral putrefaction that improves intestinal flora, the effect of improving feces character and immune activation.For example, the open dead thalline that has disclosed with enterococcus faecalis AD101 bacterial strain for communique 2001-48796 number of Japan Patent is the immunomodulator of main constituent.
It is the humoral immunization restorative of effective ingredient that Japan Patent has openly disclosed with lactobacillus or its handled thing for the flat 10-29946 of communique number, and this restorative has the effect that makes the humoral immunization functional recovery that descends because of medicament.
Japan Patent has openly disclosed with lactobacillus thalline and/or thalline for the flat 6-80575 of communique number and has contained the peroral immunity activator that thing is an effective ingredient.
Japan Patent is open to have disclosed the immune activation compositions that the Cytoplasm composition that comprises the lactobacillus thalline and/or Cytoplasm composition contain thing for the flat 5-252900 of communique number.
Summary of the invention
As mentioned above, though isotoadstool and lactobacillus are widely used as health food, the physiologic effect when they are ingested separately is not very good.
Therefore, the purpose of this invention is to provide the diet product that oral uptake can show the inhibition infected group compound of good inhibition effect to the infection of pathogen etc. and contain said composition.
Present inventors are conscientiously research back discovery in order to achieve the above object, and with the extract of isotoadstool and the heat treated thalline of lactobacillus, can show stronger inhibitory action to the infection of pathogen, thereby finish the present invention.
That is, the present invention 1 suppresses the infected group compound, and the feature of said composition is sporophore and/or the extract of mycelium culture and the heat treated thalline of lactobacillus that contains the isotoadstool (Agaricus blazei Murill) as effective ingredient.
The active synergy of immunity effect that the present invention 1 utilizes the heat treated thalline of the extract of the sporophore of isotoadstool and/or mycelium culture and lactobacillus to be possessed provides the infection to pathogen etc. to show stronger inhibiting inhibition infected group compound.
Lactobacillus among the present invention 1 is preferably enterococcus faecalis (Enterococcus faecalis).In addition, the heat treated thalline that preferably contains the aforementioned lactobacillus of the extract of the sporophore of aforementioned isotoadstool (Agaricus blazei Murill) of 0.5～99.5 quality % and/or mycelium culture and 99.5～0.5 quality %.The inhibition infected group compound that can be more effectively the infection of pathogen etc. be suppressed can be provided like this.
The present invention 2 provides the diet product that contain above-mentioned inhibition infected group compound.
Among the present invention 2, aforementioned inhibition infected group compound is preferably 0.01～10g corresponding to the content of 1 meal part.
In the inhibition infected group compound of the present invention since the heat treated thalline that contains the extract of the sporophore of the isotoadstool of taking in as food and/or mycelium culture and lactobacillus as effective ingredient, so it is more safe than in the past, by taking in above-mentioned extract and heat treated thalline, can be to good infection mitigation effects of generation such as pathogen.Inhibition infected group compound of the present invention is added in the diet product, the diet product of the infection that can prevent pathogen etc. can be provided.
Though the mechanism of action of the inhibition infectious effect of present also not clear and definite inhibition infected group compound of the present invention, but by sporophore and/or the extract of mycelium culture and the heat treated thalline of lactobacillus of taking in isotoadstool simultaneously, can make with macrophage, NK cell and T cell is the cell immune system activation at center, effective excluding pathogenic bacteria etc.
Description of drawings
Fig. 1 represents to infect the mice survival rate behind the Listeria monocytogenes.
Fig. 2 represents to infect the measurement result of the Listeria monocytogenes number in the mouse spleen behind the Listeria monocytogenes.
Fig. 3 represents by the cytokine amount (IL-2, IL-10, IL-12, IFN-γ) in the supernatant of mesenteric lymph node cell (MLN) culture fluid of ELISA method mensuration.
The specific embodiment
Sporophore extract as the isotoadstool of one of effective ingredient of inhibition infected group compound of the present invention can directly extract acquisition by water, ethanol equal solvent, and also available water, ethanol equal solvent extract its dry thing and obtain.For example, add about 20 times water of dry isotoadstool sporophore quality, carry out extracting in 30 minutes, then the gained extract is carried out suitably concentrated and dry in 120 ℃.
In addition, can cultivate by the kind bacterium to isotoadstool in the culture medium that contains carbon source and nitrogenous source, directly extraction and obtain the extract of the mycelium culture of isotoadstool perhaps extracts its dry product as previously mentioned then.
The present invention also can use the commercially available isotoadstool sporophore and/or the extract of mycelium culture.
As the heat treated thalline of the lactobacillus of another effective ingredient of inhibition infected group compound of the present invention is that the lactic acid thalline is carried out heat treated and the dead thalline that obtains, for example can obtain by the following method.
In ロ go サ culture medium, the lactobacillus cultivation after 12～72 hours, is reclaimed thalline by suitable means such as centrifugalize in 30～45 ℃.The thalline that reclaims is washed and concentrated, this after spissated thallus suspension liquid carries out the heat treated in 30 minutes～3 seconds, is carried out drying by suitable means such as spray drying and lyophilization and obtain above-mentioned dead thalline at 80～115 ℃.Above-mentioned lactobacillus comprises enterococcus faecalis, enterococcus faecalis, bacillus acidophilus, lactobacillus casei, Deshi Lactobacillus, lactobacillus helveticus, bifidobacterium longum, bifidobacterium breve, saliva chain coccus thermophilous subspecies etc.The present invention preferably uses has the active enterococcus faecalis of stronger immunity effect (ATCC 19433, and ATCC 14508, and ATCC 23655).The heat treated thalline of spendable enterococcus faecalis comprises EF POWER, EF-2001 (trade name, Konbe K.K's system) and FK-23 commercially available products such as (trade name, ニ チ ニ チ Pharmaceutical Co., Ltd systems).
The heat treated thalline that preferably comprises the aforementioned lactobacillus of the extract of the sporophore of aforementioned isotoadstool of 0.5～99.5 quality % and/or mycelium culture and 99.5～0.5 quality % in the inhibition infected group compound of the present invention.Be more preferably the heat treated thalline of the lactobacillus of the extract of the sporophore of the isotoadstool that comprises 10～90 quality % and/or mycelium culture and 90～10 quality %.If each content of effective is outside above-mentioned scope, then collaborative inhibition infectious effect is undesirable.
Except comprising above-mentioned basis, also can comprise excipient, sweeting agent, acidic flavoring agent, vitamin and mineral in the inhibition infected group compound of the present invention.In addition, its form being not particularly limited, can be powder, granule, tablet, capsule, solution etc., can do suitably to select according to the difference of application target.
Effective intake of inhibition infected group compound of the present invention is adult 1 day 0.01～10g, more preferably 0.05～2g.
Inhibition infected group compound of the present invention can add in the various diet product, for example, but beverage, frozen glue, confection, chewing gum heated food, fast food etc.The addition of above-mentioned inhibition infected group compound is preferably 0.01～10g, more preferably 0.05～2g corresponding to 1 meal part.If suppress the not enough 0.01g of addition of infected group compound, can not obtain enough inhibition infectious effects even then take in, if surpass 10g, then cost is too high.
Below, by embodiment the present invention is specifically described.Sample in the following example uses " celestial giving birth to the revealed " (trade name as the sporophore extract of isotoadstool, Kyowa Eng's system) with as " EF-2001 " (trade name, Konbe K.K's system) of the heat treated thalline of enterococcus faecalis (Enterococcus faecalis).
Test example (the acute oral toxicity test of the heat treated thalline of enterococcus faecalis)
With OECD Guidelines for the Chemicals 401 (1981) is benchmark, carries out the acute oral toxicity test with mice.
Specifically, the heat treated thalline of enterococcus faecalis is suspended in the Purified Water, modulates testing liquid (250mg/mL).
ICR to 4 ages in week is mice (each 20 of male and female, buy from Japanese エ ス エ Le シ-Co., Ltd.) after preparation raises about 1 week, they are divided into test group (each 10 of male and female) and matched group (each 10 of male and female), the mice of giving test group with gastric probe is the above-mentioned testing liquid of oral administration by force, and the heat treated biomass of enterococcus faecalis is according to the standard conversion of 5000mg/kg body weight.Pour into Purified Water (male mice 0.7mL, female mice 0.6mL) to matched group simultaneously.Then, being set at 23 ± 2 ℃ of room temperatures, raise in the receptacle in lighting hours 12 mice/skies.Duration of test, mice can freely be taken in water and feedstuff, and (" mice, rat are used solid feed to trade name; ラ ボ MR ス ト Network ", Japanese agricultural production Industrial Co., Ltd system).
After pouring into above-mentioned testing liquid and Purified Water, observed 1 time (observation period is 14 days) in 1 day, two groups dead example all do not occur.Observation period finishes the back dissects all mices, and its main organs is no abnormality seen also.In addition, pour into behind testing liquid and the Purified Water and to measure the mice body weight in the 7th day and the 14th day, with the comparison between 5% group of significance level, its result is as shown in table 1 by the t method of inspection.
Table 1
| Body weight (g) | ||||||
| Before pouring into | Poured into the back the 7th day | Poured into the back the 14th day | ||||
| Male | Female | Male | Female | Male | Female | |
| Matched group | ??30.7± ?????1.2 | ??26.7± ?????1.5 | ??34.9± ?????1.4 | ??29.2± ?????1.9 | ??37.3± ?????1.9 | ???31.0± ??????1.8 |
| Test group | ??30.7± ?????1.3 | ??27.0± ?????1.4 | ??35.5± ?????2.0 | ??29.2± ?????1.7 | ??38.3± ?????2.7 | ???31.3± ??????1.9 |
With mean+SD (n=10) expression body weight
Can find out from table 1, variant no matter each group of male and female there is no weight increase.Can find out the LD of the mice of the heat treated thalline of a per os absorption enterococcus faecalis from The above results
50Value is more than the 5000mg/kg body weight.
The BALB/c female mice (buying from Japanese Network レ ア Co., Ltd.) in 40 7 ages in week is divided into 4 groups (10 every group), respectively the mice of giving test group with gastric probe by force oral administration with the mixture of the heat treated thalline (10 μ g/) of the sporophore extraction extractum (dry sporophore 0.3mg/ only) of isotoadstool and enterococcus faecalis, the mice of giving comparable group 1 by force oral administration with the heat treated thalline (20 μ g/ only) of enterococcus faecalis, the mice of giving comparable group 2 by force oral administration with the sporophore extraction extractum (dry sporophore 0.6mg/ only) of isotoadstool, give mice in control group oral administration PBS (0.2mL/ only) by force, 1 all interior every days 1 time.
Then, in mouse peritoneal, inject Listeria monocytogenes (Listeriamonocytogenes), reach 2 * 10
5CFU/ only observes the survival rate of respectively organizing mice.Duration of test, mice can freely be taken in water and feedstuff (trade name " powder feed CE-2 ", Japanese Network レ ア Co., Ltd. system).
Its result as shown in Figure 1.As can be seen from Figure 1, test group, comparable group 1 are compared with matched group with 2, show very high survival rate.Particularly the mice of test group does not have 1 death, and the infection and the propagation of this explanation Listeria monocytogenes have obtained inhibition.
Similarly to Example 1, respectively organize mice oral administration sample by force, make the mouse infection Listeria monocytogenes then from testing to make for 1 time preceding 1 week beginning every day.Then, win the spleen of mice, measure the variation of the Listeria monocytogenes number of spleen infection.Specifically, won spleen at metainfective the 1st, 3,5,7 day, after spleen ground, be suspended among the PBS, after suspension is progressively diluted, it moved into " enriched medium of Listeria monocytogenes " (trade name, the MERCK corporate system) cultivates (25 ℃ in, 48 hours), measure the clump count that occurs, its result is as shown in Figure 2.
As can be seen from Figure 2, the Listeria monocytogenes quantity that infects back matched group after the 3rd day increases, and the bacterium number of test group, comparable group 1 and 2 reduces, and particularly the bacterium number of test group reduces large percentage.
Can find out that from these results per os is taken in the sporophore extraction extractum of isotoadstool simultaneously and the heat treated thalline of enterococcus faecalis is compared with their independent respectively absorptions, the former shows better inhibition infectious effect.
Inhibition infection effect mechanism when by the following method per os being taken in the heat treated thalline of the sporophore extraction extractum of isotoadstool and enterococcus faecalis is simultaneously inquired into.
(1) surface antigen of the positive α β of CD3 type T cell is resolved
After quarantine is checked and accepted and is finished, BALB/c mouse (female 7 ages in week of 1 week preparation raising will have been passed through, buy from Japanese チ ャ-Le ズ リ バ-Co., Ltd.) be divided into 2 groups (3 every group), respectively the mice of giving test group with gastric probe by force oral administration with the mixture (0.2mL/) of the heat treated thalline (20 μ g/ only) of the sporophore extraction extractum (dry sporophore 0.2mg/ only) of isotoadstool and enterococcus faecalis, give mice in control group oral administration PBS (0.2mL/ only) by force, 1 all interior every days 1 time.Then, go into Listeria monocytogenes, reach 1.4 * 10 from the tail vein injection of mice
4CFU/ only.Between feeding period, mice can freely be taken in water and feedstuff (trade name " powder feed CE-2 ", Japanese Network レ ア Co., Ltd. system).
The mice that killed each group on the 5th day behind the inoculation Listeria monocytogenes, win its mesenteric lymph node, clamp mesenteric lymph node with clouded glass, make it be suspended in the RPMI-1640 culture fluid (trade name that contains 10%FBS, the Invitrogen system), the excess tissue sheet is removed with stainless steel mesh in the washing back, modulates the mesenteric lymph node cell (hereinafter referred to as MLN) of test group and matched group respectively.
Each MLN is suspended in contain in the RPMI-1640 culture fluid of 10% FBS, reaches 5 * 10
5Individual/mL, in per 1 hole of 6 orifice plates (Corning Costar Co. system), add the 1mL culture fluid.Then, in per 1 hole, sneak into the splenocyte of handling through as the ametycin (consonance fermentation industry system) of stimulus object (5 * 10 from undressed BALB/c mouse
5Individual) and the dead thalline (1.0 * 10 of heating of Listeria monocytogenes
6CFU), in 37 ℃ at 5% CO
2Exist down and cultivated 48 hours.Above-mentioned undressed mice is meant did not take for the examination material and without the mice that crosses microbionation.
With 3 kinds of following traget antibodies (antibody is all bought by Becton Dickinson PharMingen company) each MLN is dyeed, carry out the parsing of cell surface antigen.
1) the anti-CD8mAb of the anti-TCR α of the anti-CD3 ε of Cy-chrome (Cy) the labelling mAb/FITC labelling β anti-CD4mAb/biotin labelling of mAb/PE labelling
2) the anti-CD8mAb of the anti-TCR α of the anti-CD3 ε of Cy labelling mAb/FITC labelling β mAb/PE labelling anti-CD 6 9mAb/biotin labelling
3) the anti-CD8mAb of the anti-TCR α of the anti-CD3 ε of the Cy labelling mAb/FITC labelling β anti-CD122mAb/biotin labelling of mAb/PE labelling
That is, be modulated into 1.0 * 10
5 Interpolation 5 μ L above-mentioned 1 in the suspension of individual MLN) traget antibody of expression, in 4 ℃ the insulation 45 minutes after, with Hank ' the s buffer washing that contains 5%FBS 2 times, add the SA-RED613 (trade name of 5 μ L again, the Invitrogen corporate system),, wash 3 times after 45 minutes in 4 ℃ of insulations with Hank ' the s buffer that contains 5%FBS.Then, carry out the surface antigen of MLN by flow cell analyzer (Epics XL, Beckman Coulter Inc. system) and resolve, try to achieve CD4
-CD8
+Cell and CD4
+CD8
-The ratio of cell compares the CD8 positive rate, and its result is as shown in table 2.
Table 2
| At all CD3 +αβTCR +Ratio in the cell (%) | |||
| MLN (mean+SD) | Ratio (B/A) | ||
| ??CD4 +CD8 -(A) | ??CD4 -CD8 +(B) | ||
| Matched group | ??29.1±1.3 | ??26.4±1.2 | ??0.9±0.3 |
| Test group | ??20.4±1.2 | ??43.7±1.2 | ??2.1±0.3 |
Can find out that from table 2 the CD8 positive rate of test group is higher approximately about 2 times than matched group, the sporophore extraction extractum of isotoadstool is taken in this explanation and the heat treated thalline of enterococcus faecalis has improved the CD8 positive rate.
In addition, it is activatory having or not of index research CD8 positive T cell with CD69 (initial activity labelling) and CD122 (IL-2 receptor β chain).That is, use above-mentioned 2) and 3) traget antibody of expression, resolving by the surface antigen that carries out cell with above-mentioned same method, its result is as shown in table 3.
Table 3
| At all CD3 +αβTCR +CD8 +Ratio in the cell (%) | ||
| MLN (mean+SD) | ||
| ????CD69 + | ????CD122 + | |
| Matched group | ????38.6±1.2 | ????35.5+1.8 |
| Test group | ????42.2±1.2 | ????43.8±1.4 |
Can find out that from table 3 all than the height of matched group, the sporophore extraction extractum of this explanation absorption isotoadstool and the heat treated thalline of enterococcus faecalis have promoted the activation of CD8 positive T cell for the CD69 of test group and CD122 positive rate.
(2) output of cytokine
With the MLN of above-mentioned same modulation matched group and test group, add stimulus object, in 37 ℃ at 5%CO
2Exist and carry out 48 hours cultivation down.
Cultivation finishes the back and reclaims culture supernatant, with the cytokine amount (IL-2, IL-10, IL-12, IFN-γ) in the ELISA method mensuration culture supernatant.Measure IL-2, IL-12 and IFN-γ with the mensuration box of buying from Endogen Inc. company, use the mensuration box mensuration IL-10 that buys from AN ' ALYZA TECHNE Co. company, its result as shown in Figure 3.
As can be seen from Figure 3, the output as the IFN-γ of t helper cell 1 (Th-1) cytokines and IL-12 of test group is very high, and is very low as the output of the IL-10 of t helper cell 2 (Th-2) cytokines.
With the expression of RT-PCR method research cytokine specific mrna, found that the expression of the mRNA of Th-1 cytokines I1-12, the IFN-γ of test group and TNF-α increases.The expression indifference of the mRNA of Th-2 cytokines IL-10.
Generally, be activated, produce IL-12 and IFN-γ respectively by macrophage and NK cell in the body of cytozoicus bacterial infections such as Listeria monocytogenes.These cytokines make the specific CD8 positive T cell activation of bacterial antigens again, and the CD8 positive T cell that consequently has cytotoxicity (CTL) is finished the antibacterial eliminating.In addition, the TNF-α that is produced by the T cell has the effect that phagocyte such as making neutrophilic granulocyte and macrophage accumulates in infection site.
Promptly, can find out from The above results, by also using the sporophore extractum and the enterococcus faecalis of isotoadstool, more promoted the activation of macrophage and NK cell, the output of IL-12 and IFN-γ etc. is increased, also promoted the activation of Listeria monocytogenes specific C D8 positive cell simultaneously, antibacterial gets rid of also fast than matched group.
As mentioned above, the invention provides the compositions with good inhibition infectious effect, said composition contains the heat treated thalline of the extract of the sporophore of isotoadstool and/or mycelium culture and enterococcus faecalis as effective ingredient.In addition, also provide the diet product of the infection that can prevent pathogen etc., added inhibition infected group compound of the present invention in these diet product.
Inhibition infected group compound of the present invention so safety is higher, is taken in the back expection and can be promoted with the cellular immunization to be the activation of the body defending system at center owing to derive from food, has the effect of the infection of prevention pathogen etc.
Claims (5)
1. suppress the infected group compound, it is characterized in that, contain sporophore and/or the extract of mycelium culture and the heat treated thalline of lactobacillus of isotoadstool (Agaricusblazei Murill) as effective ingredient.
2. inhibition infected group compound as claimed in claim 1, wherein, aforementioned lactobacillus is enterococcus faecalis (Enterococcus faecalis).
3. inhibition infected group compound as claimed in claim 1 or 2 wherein, contains the heat treated thalline of the aforementioned lactobacillus of the extract of the sporophore of aforementioned isotoadstool of 0.5～99.5 quality % and/or mycelium culture and 99.5～0.5 quality %.
4. diet product, described diet product contain each described inhibition infected group compound in the claim 1～3.
5. diet product as claimed in claim 4, wherein, 1 meal part is contained the aforementioned inhibition infected group of 0.01～10g compound.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001150643 | 2001-05-21 | ||
| JP2001150643 | 2001-05-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1386510A true CN1386510A (en) | 2002-12-25 |
| CN1269490C CN1269490C (en) | 2006-08-16 |
Family
ID=18995629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02121607XA Expired - Fee Related CN1269490C (en) | 2001-05-21 | 2002-05-21 | Composition of suppressing infection, and veberage and food contg. same |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20020089149A (en) |
| CN (1) | CN1269490C (en) |
| SG (1) | SG93936A1 (en) |
| TW (1) | TWI230611B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110234331A (en) * | 2017-01-30 | 2019-09-13 | 营养株式会社 | MRSA infects protective agent |
| CN111542330A (en) * | 2018-01-31 | 2020-08-14 | 营养株式会社 | Prophylactic and/or therapeutic agent for streptococcus pneumoniae infection |
| CN111867607A (en) * | 2018-04-19 | 2020-10-30 | 营养株式会社 | Prophylactic and/or therapeutic agent for Pseudomonas aeruginosa infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5157858A (en) * | 1974-11-15 | 1976-05-20 | Shigenobu Watari | Nyusankininryono seizohoho |
| US4110477A (en) * | 1977-05-13 | 1978-08-29 | Kabushiki Kaisha Naruse Fermentation Laboratory | Method for producing natto containing lactic acid bacteria |
| KR19980075714A (en) * | 1997-04-01 | 1998-11-16 | 김용구 | Agaricus Mushroom Containing Healthy Drink |
| JPH11113531A (en) * | 1997-10-17 | 1999-04-27 | Hudson Shoji Kk | Health food |
| JPH11130690A (en) * | 1997-10-29 | 1999-05-18 | Miyato Higaki | Immunoregulatory agent and antiinflammatory agent |
| KR19990046012A (en) * | 1999-03-10 | 1999-06-25 | 조성인 | The production method of tea or drink utilizing the myceloid Phellinus Linteus or Agaricus blazei |
| JP3627968B2 (en) * | 1999-11-04 | 2005-03-09 | 株式会社応微研 | Lactic acid fermented food and method for producing the same |
-
2002
- 2002-05-03 SG SG200202671A patent/SG93936A1/en unknown
- 2002-05-15 TW TW091110088A patent/TWI230611B/en not_active IP Right Cessation
- 2002-05-16 KR KR1020020027056A patent/KR20020089149A/en not_active Application Discontinuation
- 2002-05-21 CN CNB02121607XA patent/CN1269490C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110234331A (en) * | 2017-01-30 | 2019-09-13 | 营养株式会社 | MRSA infects protective agent |
| CN110234331B (en) * | 2017-01-30 | 2023-06-16 | 营养株式会社 | MRSA infection protectant |
| CN111542330A (en) * | 2018-01-31 | 2020-08-14 | 营养株式会社 | Prophylactic and/or therapeutic agent for streptococcus pneumoniae infection |
| CN111542330B (en) * | 2018-01-31 | 2023-09-12 | 营养株式会社 | Preventive and/or therapeutic agent for Streptococcus pneumoniae infection |
| CN111867607A (en) * | 2018-04-19 | 2020-10-30 | 营养株式会社 | Prophylactic and/or therapeutic agent for Pseudomonas aeruginosa infection |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI230611B (en) | 2005-04-11 |
| KR20020089149A (en) | 2002-11-29 |
| CN1269490C (en) | 2006-08-16 |
| SG93936A1 (en) | 2003-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nayak | Probiotics and immunity: a fish perspective | |
| Hetland et al. | Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer | |
| CN100341521C (en) | Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition | |
| Van Doan et al. | Effects of Eryngii mushroom (Pleurotus eryngii) and Lactobacillus plantarum on growth performance, immunity and disease resistance of Pangasius catfish (Pangasius bocourti, Sauvage 1880) | |
| Park et al. | The effect of mistletoe, Viscum album coloratum, extract on innate immune response of Nile tilapia (Oreochromis niloticus) | |
| Hayatgheib et al. | A review of functional feeds and the control of Aeromonas infections in freshwater fish | |
| EP2931289B1 (en) | Chitin or derivatives thereof for the prevention and/or treatment of parasitoses | |
| Van Doan et al. | Mushrooms, seaweed, and their derivatives as functional feed additives for aquaculture: an updated view | |
| Shojadoost et al. | Effects of treatment with lactobacilli on necrotic enteritis in broiler chickens | |
| Hardi et al. | Synbiotic application to enhance growth, immune system, and disease resistance toward bacterial infection in catfish (Clarias gariepinus) | |
| Das et al. | Organic cranberry pomace and its ethanolic extractives as feed supplement in broiler: impacts on serum Ig titers, liver and bursal immunity | |
| Ali et al. | Heat-killed Limosilactobacillus reuteri PSC102 ameliorates impaired immunity in cyclophosphamide-induced immunosuppressed mice | |
| Carter et al. | Control strategies for Salmonella colonization of poultry: The probiotic perspective | |
| CN1269490C (en) | Composition of suppressing infection, and veberage and food contg. same | |
| Herich et al. | The effect of Lactobacillus paracasei and Raftilose P95 upon the non-specific immune response of piglets | |
| JP4499979B2 (en) | Composition for controlling pathogen infection | |
| US20210261912A1 (en) | Method for preparing composition comprising killed or inactivated methanobrevibacter archaebacteria cells and composition thereby obtained | |
| Eze et al. | Effects of Lactobacillus spp. isolated from the sap of palm tree Elaeis guineensis (palm wine) on cellular and innate immunity | |
| JP5525180B2 (en) | Immunostimulating agent, immunostimulating composition containing the same, and immunostimulating method | |
| CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal | |
| CN1178674C (en) | Bacteriostatic compositions for salmonellae | |
| CN103751223A (en) | Infection-suppressing composition, and food containing the same | |
| Nikapitiya | Marine bacteria as probiotics and their applications in aquaculture | |
| JP6117336B2 (en) | Newly isolated Bacillus licheniformis and probiotics using it | |
| CN104666366A (en) | Infection-inhibiting composition and food and drink containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 |